Recent Advances on Sensor Technologies for the Monitoring of Tumor Markers.

Sensor technologies have been increasingly recognized as a cornerstone for advancing tumor diagnostics amid the global health challenge posed by cancer. Traditional diagnostic methods are often constrained by inherent tumor heterogeneity, while liquid biopsy has emerged as a transformative minimally invasive alternative, with biosensors playing a pivotal role in its clinical translation. This review summarizes the progress of tumor diagnostic biosensors, focusing on electrochemical and fluorescent sensors. Electrochemical sensors excel in quantitative precision, miniaturization, and point-of-care (POCT) applicability, enabling ultra-sensitive detection of biomarkers such as circulating tumor cells, circulating tumor DNA, and exosomes through nanomaterial modification and signal amplification strategies. Fluorescent sensors, meanwhile, offer superior multiplexing capability and in situ imaging performance, which are further enhanced by novel nanomaterials. Additionally, it covers other promising sensor types including Surface-Enhanced Raman Scattering, microfluidic, photoelectrochemical, field-effect transistor, and clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins-based sensors. Current research efforts are concentrated on multiplexed detection, point-of-care integration, and translation toward higher-order clinical functions such as cancer subtype discrimination, risk stratification, and prognosis. Future directions will focus on multimodal integration, intelligent data analysis, and prospective clinical validation against hard endpoints to facilitate the implementation of precision oncology.